My work involves the development of novel therapeutics for malignant primary brain tumors. Our investigations in glioblastoma emphasize the development of imaging and tumor markers of sensitivity and resistance to anti-angiogenic therapeutics in preclinical models and humans. We employ novel MRI and PET imaging techniques in order to define subpopulations of glioblastoma patients most likely to benefit from agents targeting vascular endothelial growth factor (VEGF). We are also involved in defining and exploiting alternative pro-angiogenic targets in order to augment and extend responses to anti-VEGF therapeutics. I am also involved in early phase human trials of targeted therapeutics in molecularly defined subsets of glioblastoma.
I have played central roles in defining the optimal diagnostic and treatment pathways for primary CNS diffuse large B-cell lymphoma (PCNSL). I co-founded the International PCNSL Collaborative Group more than a decade ago and I remain the chair of this organization of over 125 hematologists, neurologists and oncologists from more than 20 countries. In the setting of local, national and international studies we have established the currently recommended diagnostic evaluation for newly diagnosed PCNSL patients. I have also spearheaded key chemotherapy trials for PCNSL contributing to currently recommended treatment guidelines for PCNSL.